EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting neutral sphingomyelinase enhances NK cell-mediated immunity via the CXCL10–CXCR3 axis in murine bladder cancer cells

Yuichi Koyama iD, Masakatsu Takanashi iD

Cancer Immunology, Immunotherapy · 13.08.2026

DOI: 10.1007/s00262-026-04518-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 13.08.2026. Verfasst von Yuichi Koyama und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pathology, School of Life and Environmental Sciences, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa, 252-5201, Jap…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Sphingomyelin Phosphodiesterase, Chemokine CXCL10, Receptors, CXCR3. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urothelial carcinoma (UC) often exhibits a “cold” tumor microenvironment with limited immune cell infiltration, leading to resistance to immune checkpoint inhibitors. Neutral sphingomyelinase (nSMase) is a key regulator of extracellular vesicle (EV) biogenesis, and pharmacological inhibition of nSMase using GW4869 has been widely used to modulate EV biogenesis. However, its impact on EV dynamics and anti-tumor immunity remains unclear. Using the syngeneic murine UC cell line, MBT-2, we assessed the effects of GW4869 on gene expression and protein secretion using RNA sequencing and enzyme-linked immunosorbent assays. Natural killer (NK) cell function was evaluated using lactate dehydrogenase cytotoxicity assays and CD107a degranulation analysis, and public datasets were analyzed to examine the clinical relevance of C-X-C motif chemokine ligand 10 (CXCL10) expression in human UC. GW4869 treatment was associated with altered EV dynamics, characterized by increased particle yields and changes in EV size distribution. Functional assays demonstrated that GW4869-treated tumor cells enhanced NK cell-mediated cytotoxicity and degranulation, and this anti-tumor effect was augmented by programmed cell death ligand 1 (PD-L1) blockade. These effects were attenuated by C-X-C motif chemokine receptor 3 (CXCR3) neutralization, suggesting the involvement of the CXCL10–CXCR3 axis. Clinically, high CXCL10 expression was associated with favorable survival outcomes and positively correlated with NK cell-associated markers in patients with UC. In conclusion, pharmacological nSMase inhibition modulates EV and secretome dynamics and promotes NK cell activation associated with the CXCL10–CXCR3 axis. These findings support further investigation of nSMase-targeted strategies for enhancing anti-tumor immunity in UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalSphingomyelin PhosphodiesteraseChemokine CXCL10Receptors, CXCR3Urinary Bladder NeoplasmsBenzylidene CompoundsAniline CompoundsImmunity, CellularAnimalsMiceHumansCell Line, TumorTumor MicroenvironmentSignal Transduction

Stichwörter der Autor:innen

CXCL10GW4869Immune checkpoint blockadeNK cellsUrothelial carcinomanSMase

Substanzen

Sphingomyelin PhosphodiesteraseChemokine CXCL10Receptors, CXCR3GW 4869Benzylidene CompoundsAniline CompoundsCxcr3 protein, mouseCxcl10 protein, mouse

Autor:innen und Institutionen

  • Laboratory of Pathology, School of Life and Environmental Sciences, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa, 252-5201, Japan. y-koyama@azabu-u.ac.jp.
  • Laboratory of Pathology, School of Life and Environmental Sciences, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa, 252-5201, Japan.

ORCID-Profile: Yuichi Koyama, Masakatsu Takanashi

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Koyama, Y., & Takanashi, M. (2026). Targeting neutral sphingomyelinase enhances NK cell-mediated immunity via the CXCL10–CXCR3 axis in murine bladder cancer cells. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04518-5

Vancouver

Koyama Y, Takanashi M. Targeting neutral sphingomyelinase enhances NK cell-mediated immunity via the CXCL10–CXCR3 axis in murine bladder cancer cells. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04518-5

BibTeX
@article{Koyama2026,
  author = {Koyama, Yuichi and Takanashi, Masakatsu},
  title = {Targeting neutral sphingomyelinase enhances NK cell-mediated immunity via the CXCL10–CXCR3 axis in murine bladder cancer cells},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04518-5}
}
Kostenlos starten →